Amgen traded certain ex-US rights to its Phase III calcitonin gene-related peptide (CGRP) inhibitor for migraine headaches to acquire shared global rights to Novartis's early-stage candidate for Alzheimer's disease, raising an important question: Who is getting the better deal?
The answer probably won't be known until the companies commercialize their lead migraine and Alzheimer's candidates, but both indications have...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
